Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

VRML $1.39 0.0800 +6.11%
KERX $5.44 0.1800 +3.42%
MDVN $57.80 1.6300 +2.90%
NLNK $16.21 0.3300 +2.08%
MNTA $9.51 0.1900 +2.04%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

IMGN $6.85 -1.6000 -18.93%
ARGS $6.24 -0.8500 -11.99%
GILD $88.21 -8.7900 -9.06%
OMED $12.40 -1.1700 -8.62%
AGEN $3.52 -0.3200 -8.33%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next > | Last >>

Watercress Extract Detoxifies Carcinogens In Smokers, Clinical Trial Demonstrates

(UPMC) Apr 19, 2016 - Taken multiple times a day, watercress extract significantly inhibits carcinogen activity in smokers, a Pitt clinical trial showed.
read press release 

Breast Cancer Stem Cells Radicalize Normal Neighbors For Purpose Of Metastasis

(UCCC/Colorado Cancer Blogs) Apr 18, 2016 - A University of Colorado Cancer Center study presented at the American Association for Cancer Research Annual Meeting 2016 shows that stem-like breast cancer cells secrete molecules that allow neighboring, otherwise anchored cells to metastasize.
read article 

Low-fat Diet Reduces Risk Of Breast Cancer And Subsequent Death

(Fred Hutch News Service) Apr 18, 2016 - Women’s Health Initiative study indicates benefit to low-fat, fruit and veggie-rich diet.
read article 

Indian-American Scientist Creates T-Cells To Treat Pancreatic Cancer

(The Times of India/IANS) Apr 19, 2016 - An Indian-American scientist has engineered T-cells - a type of immune cells - to break the pancreatic cancer's physical and immunological walls using immunotherapy.
read article 

Progress in ‘Precision Prevention’ For Colorectal Cancer

(Fred Hutch News Service) Apr 18, 2016 - New risk prediction model — not yet ready for clinical use — incorporates genetic, lifestyle and environmental risk factors.
read article 

Preliminary Study: Antibody Therapy Reduces Cancer Stem Cells in Multiple Myeloma

(Johns Hopkins Medicine) Apr 15, 2016 - An experimental antibody treatment decreased by half the number of cancer stem cells that drive the growth of tumors in nearly all patients with multiple myeloma, a cancer of the bone marrow and bone tissue, according to results of a preliminary clinical trial led by Johns Hopkins Kimmel Cancer Center scientists.
read press release 

New Biomarker Data To Be Presented at AACR Helps Predict Overall Survival in Patients with Acute Myeloid Leukemia (AML) Treated with Ceplene® and Low-dose IL-2 Immunotherapy, Including Those Over 60 Years of Age

(Immune Pharmaceuticals) Apr 19, 2016 - Previous phase III study had demonstrated improvement of over 130% in 3 year leukemia free survival in M4-M5 AML subtype patients under 60 years of age.
read corporate press release 

Experimental Drug Guadecitabine Found Safe in Patients with Colorectal Cancer

(Johns Hopkins Medicine) Apr 15, 2016 - In a small, phase I clinical trial, Johns Hopkins Kimmel Cancer Center researchers say they show for the first time that the experimental drug guadecitabine (SGI-110) is safe in combination with the chemotherapy drug irinotecan and may overcome resistance to irinotecan in patients with metastatic colorectal cancer.
read press release 

Triphase Accelerator Corporation Announces Positive Interim Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma

(PM360) Apr 19, 2016 - Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced positive results from its ongoing Phase 1 proof-of-concept study evaluating marizomib in combination with bevacizumab in patients with WHO grade IV malignant glioma.
read article 

DelMar Pharmaceuticals Updates Ongoing Phase I/II Refractory GBM Clinical Trial with VAL-083 at American Association Cancer Research (AACR) Annual Meeting

(Yahoo! Finance) Apr 19, 2016 - Results to date support the potential of VAL-083 as a new treatment paradigm for GBM patients who have failed or are unlikely to respond to currently available treatments.
read article 

Penn-led Team Presents Results from Clinical Trial of Personalized Cellular Therapy in Brain Tumor Patients

(Penn Medicine) Apr 18, 2016 - Immune cells engineered to seek out and attack a type of deadly brain cancer known as glioblastoma (GBM) were found to have an acceptable safety profile and successfully migrate to and infiltrate tumors, researchers from Penn Medicine and Harvard University reported at the AACR Annual Meeting 2016 (Abstract LB-083).
read press release 

Study: No Escape From Loxo-101 for TRK-fusion Lung Cancer

(UCCC/Colorado Cancer Blogs) Apr 17, 2016 - Study pinpoints ways that cancer cells evolve to resist the drug LOXO-101, a kinase inhibitor of the TRK-fusion genes that drive a subset of cancers. The drug is currently being evaluated in promising phase 1 and phase 2 clinical trials.
read article 

Galena Biopharma Presents GALE-301/GALE-302 Clinical Booster Data at the American Association for Cancer Research (AACR) Annual Meeting

(EconoTimes) Apr 19, 2016 - Galena Biopharma, Inc. today announced that data from the booster phase of the Company’s GALE-301/GALE-302 Phase 1/2a clinical trial was presented at the American Association for Cancer Research (AACR) Annual Meeting.
read article 

Cerulean Announces Presentation at 2016 American Association for Cancer Research Annual Meeting of Stage 1 Data from Phase 2 Trial in Platinum-Resistant Ovarian Cancer

(Yahoo! Finance) Apr 19, 2016 - Late-Breaker presents results from investigator-sponsored trial of CRLX101 in combination with Avastin® (bevacizumab) in patients with platinum-resistant ovarian cancer.
read article 

Entrectinib: Targeting NTRKs, ROS1, ALK Appears Promising

(Medscape Medical News) Apr 19, 2016 - An investigational agent that targets TrkA/B/C, ROS1, and ALK gene fusions has shown objective response rates (ORR) of over 80% across several solid tumors, according to updated data presented here at the American Association for Clinical Research (AACR) annual meeting. The new drug, entrectinib, is being developed by Ignyta.
read article (free registration required) 

An Implantable Microdevice Has Potential to Identify Suitable Therapy for Cancer Patients

(AACR) Apr 19, 2016 - A microdevice implanted into a tumor could release up to 100 individual cancer therapeutics or combinations, and upon retrieval from the tumor and analyses, could identify the best treatment option for that tumor, according to preclinical research presented here at the AACR Annual Meeting 2016, April 16-20.
read press release 

New Mathematical Model May Help Better Define Roles of Environmental and Intrinsic Factors in Cancer Initiation

(AACR) Apr 19, 2016 - A mathematical model that takes into account the number of mutations required to initiate a specific type of cancer to estimate mutational activity, rather than cancer initiation, as the elementary event (as reported in two studies last year, one of which generated the "bad luck" hypothesis) may help better define the contributions of environmental factors and cellular factors in cancer initiation, according to data presented here at the AACR Annual Meeting 2016, April 16-20.
read press release 

New Technology Can Potentially Overcome CAR T-cell Immunotherapy Limitations

(AACR) Apr 19, 2016 - An engineered organic bispecific adaptor molecule that functions as a bridge between a chimeric antigen receptor (CAR) T cell and a cancer cell can potentially overcome some of the limitations posed by CAR T-cell immunotherapy technologies, according to data presented here at the AACR Annual Meeting 2016, April 16-20.
read press release 

Noninvasive Test Detected Colorectal Cancer in Previously Unscreened Patients

(AACR) Apr 19, 2016 - A noninvasive colorectal cancer screening test detected the disease in patients who had previously avoided more invasive screening measures, according to research presented here at the AACR Annual Meeting 2016, April 16-20. The study of nearly 400 patients revealed four patients with cancers and 21 with advanced adenoma, or polyps.
read press release 

Agendia’s MammaPrint® First and Only Genomic Assay to Receive Level 1A Clinical Utility Evidence for Chemotherapy Benefit in Early Breast Cancer Patients

(Agendia) Apr 18, 2016 - Agendia, Inc., together with the European Organisation for Research and Treatment of Cancer (EORTC) and Breast International Group (BIG), announced results from the initial analysis of the primary objective of the Microarray In Node-negative (and 1 to 3 positive lymph node) Disease may Avoid ChemoTherapy (MINDACT) study at the American Association for Cancer Research Annual Meeting 2016 in New Orleans, LA.
read corporate press release 

Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting

(Merck) Apr 19, 2016 - Merck, known as MSD outside the United States and Canada, is proud to be a part of the Blueprint PD-L1 Assay Comparison Project, an important initiative to compare several new diagnostic tests for the immune biomarker PD-L1 in non-small cell lung cancer (NSCLC).
read corporate press release 

Delays in Radiation Therapy Increase Chance of Breast Tumor Development in Women Treated for Ductal Carcinoma in Situ

(AACR) Apr 18, 2016 - Women who underwent treatment for ductal carcinoma in situ (DCIS), a noninvasive breast abnormality, were at higher risk of developing malignant breast tumors if they did not receive timely radiation therapy as part of their treatment, according to a study presented here at the AACR Annual Meeting 2016, April 16-20.
read press release 

Immunotherapy Drug Shrinks Tumors in Half of Patients with Rare, Virus-Linked Skin Cancer

(Johns Hopkins Medicine) Apr 19, 2016 - In a clinical trial of the immunotherapy drug pembrolizumab, half of 25 patients with a rare type of virus-linked skin cancer called Merkel cell carcinoma experienced substantial tumor shrinkage lasting nearly three times as long, on average, than with conventional chemotherapy.
read press release 

First Presentation of Overall Survival Data for Opdivo® (nivolumab) Shows Significant Survival Benefit at One-Year Versus Investigator’s Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

(StreetInsider) Apr 19, 2016 - Bristol-Myers Squibb Company announced today the first presentation of data from CheckMate -141, a Phase 3 open-label, randomized trial, evaluating Opdivo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after platinum therapy compared to investigator’s choice of therapy (methotrexate, docetaxel, or cetuximab).
read article 

Bristol-Myers's Opdivo Extends Survival in Head, Neck Cancer

(Bloomberg) Apr 19, 2016 - Drug lengthened median survival to 7.5 months from 5.1 months; one-year survival was 36% for Opdivo, 17% for current therapy.
read article